Abstract
The bare-metal Tryton Side Branch (SB) Stent™ (Tryton Medical, Durham, NC, USA) is used with a drug-eluting stent (DES) in the main branch (MB) to treat bifurcation lesions. It is argued that a drug-eluting Tryton-version is needed to improve clinical outcomes, although previous registries have shown good clinical results. More insights in neo-intimal hyperplasia (NIH) growth patterns of the Tryton treatment strategy are needed to decide if and where to drug-coat the stent. Ten patients returned for follow-up angiography (mean follow-up time 393 ± 103 days) and optical coherence tomography (OCT) pullbacks from the MB were obtained in all patients and from the SB in six patients. A per-strut analysis showed an uncovered strut rate of 0.7 % and an incompletely-apposed strut rate of 0.8 %. Most incompletely-apposed struts were found at the bifurcation region, in the luminal half facing towards the SB. Mean NIH thickness in the proximal MB, distal MB and SB were 0.14 ± 0.11, 0.19 ± 0.11, and 0.34 ± 0.19 mm, respectively, with a variety of growth patterns observed in the SB. We found good vascular healing of the DES in the MB, while healing was less favourably in the SB part. Furthermore, we observed a variety of NIH growth patterns in this SB part and more studies are needed to investigate the relation between growth patterns and clinical outcomes.
Similar content being viewed by others
References
Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E et al (2012) Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish coronary angiography and angioplasty registry (SCAAR). Eur Heart J 33(5):606–613
Rathore S, Terashima M, Katoh O, Matsuo H, Tanaka N, Kinoshita Y et al (2009) Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention 5(3):349–354
van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ et al (2009) Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 53(16):1399–1409
Kaplan AV, Davis HR (2006) Tryton side-branch stent. EuroIntervention 2(2):270–271
Onuma Y, Muller R, Ramcharitar S, van Geuns RJ, Louvard Y, Morel MA et al (2008) Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. EuroIntervention 3(5):546–552
Magro M, Wykrzykowska J, Serruys PW, Simsek C, Nauta S, Lesiak M et al (2011) Six-month clinical follow-up of the Tryton side branch stent for the treatment of bifurcation lesions: a two center registry analysis. Catheter Cardiovasc Interv 77(6):798–806
Agostoni P, Foley D, Lesiak M, Belkacemi A, Dens J, Kumsars I et al (2012) A prospective multicentre registry, evaluating real-world usage of the Tryton side branch stent: results of the E-Tryton 150/Benelux registry. EuroIntervention 7(11):1293–1300
Grundeken MJ, Smits M, Harskamp RE, Damman P, Woudstra P, Hoorweg AJ et al (2012) Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions. Neth Heart J 20(11):439–446
Grundeken MJ, Asgedom S, Damman P, Lesiak M, Norell MS, Garcia E et al (2013) Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. EuroIntervention 9(2):195–203
Nakazawa G, Yazdani SK, Finn AV, Vorpahl M, Kolodgie FD, Virmani R (2010) Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. J Am Coll Cardiol 55(16):1679–1687
Zimarino M, Corazzini A, Ricci F, Di NM, De CR (2013) Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational studies. JACC Cardiovasc Interv 6(7):687–695
Magro M, van Geuns RJ (2010) TheTryton side branch stent. EuroIntervention 6(Suppl J):J147–J150
Medina A, de Suarez LJ, Pan M (2006) A new classification of coronary bifurcation lesions. Rev Esp Cardiol 59(2):183
Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D et al (2009) Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv 2(5):459–466
Dubois C, Adriaenssens T, Ughi G, Wiyono IS, Bennett J, Coosemans M et al (2012) Healing responses after bifurcation stenting with the dedicated TRYTON side-branch Stent (TM) in combination with XIENCE-V (TM) stents: a clinical, angiography, fractional flow reserve and optical coherence tomography study. Catheter Cardiovasc Interv 81(3):E155–E164
Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M et al (2005) A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1(1):58–65
Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ et al (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2(3):286–294
Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299(16):1903–1913
Kozuma K, Kimura T, Kadota K, Suwa S, Kimura K, Iwabuchi M et al (2013) Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: angiographic sub-study from the Randomized Evaluation of sirolimus-eluting versus everolimus-eluting stent Trial (RESET). Cardiovasc Interv Ther 28(4):344–351
Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G et al (2011) The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 57(22):2221–2232
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M et al (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346(23):1773–1780
Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM et al (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43(6):1110–1115
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T et al (2006) Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114(8):798–806
Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S et al (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108(7):788–794
Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A (1999) Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol 83(12):1617–1622
Hikichi Y, Inoue T, Node K (2009) Benefits and limitations of cypher stent-based bifurcation approaches: in vitro evaluation using micro-focus CT scan. J Interv Cardiol 22(2):128–134
Murasato Y, Hikichi Y, Horiuchi M (2009) Examination of stent deformation and gap formation after complex stenting of left main coronary artery bifurcations using microfocus computed tomography. J Interv Cardiol 22(2):135–144
Shiratori Y, Brugaletta S, Alvarez-Contreras L, Azpeitia Y, Ospino N, Gaido S, et al. (2013) One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study. Catheter Cardiovasc Interv 82(4):E428–E436
Gomez-Lara J, Brugaletta S, Farooq V, Onuma Y, Diletti R, Windecker S et al (2011) Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. JACC Cardiovasc Interv 4(12):1271–1280
Kim SJ, Lee H, Cho JM, Park CB, Kim W, Kato K et al (2013) Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study. Coron Artery Dis 24(5):431–439
Gutierrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbaek H, Saunamaki K et al (2011) Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J 32(19):2454–2463
Goto I, Itoh T, Kimura T, Fusazaki T, Matsui H, Sugawara S et al (2011) Morphological and quantitative analysis of vascular wall and neointimal hyperplasia after coronary stenting: comparison of bare-metal and sirolimus-eluting stents using optical coherence tomography. Circ J 75(7):1633–1640
Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N et al (2011) Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 123(3):274–281
Foin N, Torii R, Alegria E, Sen S, Petraco R, Nijjer S et al (2013) Location of side branch access critically affects results in bifurcation stenting: insights from bench modeling and computational flow simulation. Int J Cardiol 168(4):3623–3628
Alegria-Barrero E, Foin N, Chan PH, Syrseloudis D, Lindsay AC, Dimopolous K et al (2012) Optical coherence tomography for guidance of distal cell recrossing in bifurcation stenting: choosing the right cell matters. EuroIntervention 8(2):205–213
Okamura T, Yamada J, Nao T, Suetomi T, Maeda T, Shiraishi K et al (2011) Three-dimensional optical coherence tomography assessment of coronary wire re-crossing position during bifurcation stenting. EuroIntervention 7(7):886–887
Gutierrez-Chico JL, Regar E, Nuesch E, Okamura T, Wykrzykowska J, Di MC et al (2011) Delayed coverage in malapposed and side-branch struts with respect to well-apposed struts in drug-eluting stents: in vivo assessment with optical coherence tomography. Circulation 124(5):612–623
Conflict of interest
Maik Grundeken and Joanna Wykrzykowska receive consultancy fees from Tryton Medical. None of the other authors declared any relevant conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grundeken, M.J., Garcia-Garcia, H.M., Kraak, R.P. et al. Side branch healing patterns of the Tryton dedicated bifurcation stent: a 1-year optical coherence tomography follow-up study. Int J Cardiovasc Imaging 30, 1445–1456 (2014). https://doi.org/10.1007/s10554-014-0504-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10554-014-0504-y